These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36645458)

  • 1. A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin's lymphoma.
    Gaudio F; Loseto G; Bozzoli V; Scalzulli PR; Mazzone AM; Tonialini L; Fesce V; Quintana G; De Santis G; Masciopinto P; Arcuti E; Clemente F; Scardino S; Tarantini G; Pastore D; Melillo L; Pavone V; Maggi A; Carella AM; Di Renzo N; Guarini A; Musto P
    Ann Hematol; 2023 Feb; 102(2):385-392. PubMed ID: 36645458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
    Pavone V; Mele A; Carlino D; Specchia G; Gaudio F; Perrone T; Mazza P; Palazzo G; Guarini A; Loseto G; Eleonora P; Cascavilla N; Scalzulli P; Melpignano A; Quintana G; Di Renzo N; Tarantini G; Capalbo S
    Ann Hematol; 2018 Oct; 97(10):1817-1824. PubMed ID: 30054707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and safety of programmed death-1 inhibitor in the treatment of relapsed/refractory classical Hodgkin's lymphoma].
    Shan DD; Liu HM; Liu W; Huang WY; Lyu R; Deng SH; Yi SH; An G; Xu Y; Sui WW; Wang TY; Fu MW; Zhao YZ; Qiu LG; Zou DH
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jul; 44(7):555-560. PubMed ID: 37749034
    [No Abstract]   [Full Text] [Related]  

  • 4. Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?
    Othman T; Herrera A; Mei M
    Curr Hematol Malig Rep; 2021 Feb; 16(1):1-7. PubMed ID: 33409966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
    Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
    Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
    Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J
    Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center.
    Kopińska A; Koclęga A; Wieczorkiewicz-Kabut A; Woźniczka K; Kata D; Włodarczyk M; Helbig G
    Pathol Oncol Res; 2021; 27():1609867. PubMed ID: 34385892
    [No Abstract]   [Full Text] [Related]  

  • 8. Outcomes of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphomas: A Retrospective Multicenter Experience by the Rete Ematologica Pugliese (REP).
    Gaudio F; Mazza P; Carella AM; Mele A; Palazzo G; Pisapia G; Carluccio P; Pastore D; Cascavilla N; Specchia G; Pavone V
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):35-40. PubMed ID: 30293754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.
    Beköz H; Karadurmuş N; Paydaş S; Türker A; Toptaş T; Fıratlı Tuğlular T; Sönmez M; Gülbaş Z; Tekgündüz E; Kaya AH; Özbalak M; Taştemir N; Kaynar L; Yıldırım R; Karadoğan I; Arat M; Pepedil Tanrıkulu F; Özkocaman V; Abalı H; Turgut M; Kurt Yüksel M; Özcan M; Doğu MH; Kabukçu Hacıoğlu S; Barışta I; Demirkaya M; Köseoğlu FD; Toprak SK; Yılmaz M; Demirkürek HC; Demirkol O; Ferhanoğlu B
    Ann Oncol; 2017 Oct; 28(10):2496-2502. PubMed ID: 28961828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
    Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
    Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
    Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
    Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab for the Treatment of Relapsed and Refractory Classical Hodgkin Lymphoma After Autologous Transplant and in Transplant-Naïve Patients.
    Halahleh K; Al Sawajneh S; Saleh Y; Shahin O; Abufara A; Ma'koseh M; Abdel-Razeq R; Barakat F; Abdelkhaleq H; Al-Hassan N; Atiyyat R; Al-Faker N; Omari Z; Ghatasheh H; Jaradat I; Muradi I; Iyad S; Bazarbachi A
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):589-595. PubMed ID: 35490153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.
    Herrera AF; Chen L; Nieto Y; Holmberg L; Johnston P; Mei M; Popplewell L; Armenian S; Cao T; Farol L; Sahebi F; Spielberger R; Chen R; Nademanee A; Puverel S; Nwangwu M; Lee P; Song J; Skarbnik A; Kennedy N; Peters L; Rosen ST; Kwak LW; Forman SJ; Feldman T
    Lancet Haematol; 2023 Jan; 10(1):e14-e23. PubMed ID: 36403579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
    O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
    Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents.
    Spinner MA; Sica RA; Tamaresis JS; Lu Y; Chang C; Lowsky R; Frank MJ; Johnston LJ; Miklos DB; Muffly LS; Negrin RS; Rezvani AR; Shiraz P; Shizuru JA; Weng WK; Binkley MS; Hoppe RT; Advani RH; Arai S
    Blood; 2023 Jun; 141(22):2727-2737. PubMed ID: 36857637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Brentuximab vedotin and immune checkpoint inhibitors for the treatment of Hodgkin lymphoma].
    Maruyama D
    Rinsho Ketsueki; 2020; 61(8):890-900. PubMed ID: 32908053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma.
    Casadei B; Argnani L; Morigi A; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Cavo M; Zinzani PL
    Cancer Med; 2020 Nov; 9(21):7830-7836. PubMed ID: 32881376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States.
    Lurain K; Zarif TE; Ramaswami R; Nassar AH; Adib E; Abdel-Wahab N; Chintapally N; Drolen CE; Feldman T; Haykal T; Nebhan CA; Thiruvengadam SK; Li M; Mittra A; Lorentsen M; Kim C; Drakaki A; Morse M; Johnson DB; Mangla A; Dittus C; Ravi P; Baiocchi RA; Chiao EY; Rubinstein PG; Yellapragada SV; LaCasce AS; Sonpavde GP; Naqash AR; Herrera AF
    Clin Lymphoma Myeloma Leuk; 2024 Aug; 24(8):523-530. PubMed ID: 38714474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).
    Goldkuhle M; Dimaki M; Gartlehner G; Monsef I; Dahm P; Glossmann JP; Engert A; von Tresckow B; Skoetz N
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012556. PubMed ID: 30001476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of chemotherapy to nivolumab after PD-1 inhibitor failure as bridge to allogeneic stem cell transplantation in classical Hodgkin's lymphoma: report on three cases and literature review.
    Romero S; Balaguer-Roselló A; Montoro J; Beneit P; Martínez A; Ruiz C; Andreu R; Guerreiro M; Arnao M; Montava A; Vicente AI; Jarque I; Sanz J
    Ther Adv Hematol; 2021; 12():20406207211038181. PubMed ID: 34434538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.